Jan 22, 2023
The American College of Cardiology (ACC) has a long history of developing documents (eg, decision pathways, health policy statements, appropriate use criteria) to…
Jan 19, 2023
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a morbid condition, though recent advances in diagnosis and therapy stand to change its natural…
Dec 06, 2022
Amyloidosis is a collection of diseases caused by the misfolding of proteins that aggregate into insoluble amyloid fibrils and deposit in tissues. While these…
Nov 28, 2022
Background: Diagnostic and therapeutic advances have led to much greater awareness of transthyretin cardiac amyloidosis (ATTR-CA). We aimed to characterize changes…
Nov 23, 2022
The Nomenclature Committee of the International Society of Amyloidosisexternal link, opens in a new tab met at the XVIII International Symposium on Amyloidosis in…
Nov 14, 2022
Amyloid light chain (AL) amyloidosis - a progressive disorder caused by misfolded light chains produced by plasma cells - is associated with high mortality, poor…
Jul 22, 2022
Background: The study objective was to assess the effect of vutrisiran, an RNA interference therapeutic that reduces transthyretin (TTR) production, in patients…
Jul 13, 2022
AL amyloidosis is a life-threatening disease related to bone marrow cancer, multiple myeloma. It is caused when a person's antibody-producing white blood cells (i.e…
Jun 01, 2022
The recent approval of three drugs for the treatment of amyloid transthyretin (ATTR) amyloidosis, both hereditary and wild-type, has opened a new era in the care of…